330
Participants
Start Date
April 4, 2021
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2023
antiviral prophylaxis with Tenofovir Alafenamide Fumarate
All participants will receive antiviral prophylaxis with Tenofovir Alafenamide Fumarate for preventing of Mother-to-child transmission of HBV
RECRUITING
The First Affiliated Hospital of Jilin University, Changchun
RECRUITING
The First People's Hospital of Foshan, Foshan
RECRUITING
Guangdong Maternal and Child Care Hospital, Guangzhou
ACTIVE_NOT_RECRUITING
Guangzhou No. 8 People's Hospital, Guangzhou
RECRUITING
Nanfang Hospital, Southern Medical University, Guangzhou
ACTIVE_NOT_RECRUITING
The Fifth Affiliated Hospital of Southern Medical University, Guangzhou
ACTIVE_NOT_RECRUITING
Zhujiang Hospital, Southern Medical University, Guangzhou
RECRUITING
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou
ACTIVE_NOT_RECRUITING
Xixi Hospital of Hangzhou, Hangzhou
RECRUITING
The Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine (The Second Hospital of Nanjing), Nanjing
RECRUITING
Shanghai Public Health Clinical Center, Shanghai
RECRUITING
Shenzhen Baoan Maternal and Child Care Hospital, Shenzhen
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Collaborators (1)
Gilead Sciences
INDUSTRY
Tigermed Consulting Co., Ltd
INDUSTRY
Nanfang Hospital, Southern Medical University
OTHER